Candidate Topical Microbicides Bind Herpes Simplex Virus Glycoprotein B and Prevent Viral Entry and Cell-to-Cell Spread
暂无分享,去创建一个
Robert A. Anderson | N. Cheshenko | B. Herold | A. Profy | L. Zaneveld | M. Keller | Albert T. Profy | G. Jarvis | D. Waller | M. Klotman | Veronica MasCasullo | Hui Cheng | Natalia Cheshenko | Marla J. Keller | Veronica MasCasullo | Gary A. Jarvis | Minnie John | Jin-Hua Li | Kathleen Hogarty | Donald P. Waller | Lourens J. D. Zaneveld | Mary E. Klotman | Betsy C. Herold | Minnie John | Kathleen Hogarty | Hui Cheng | Jin-hua Li | R. Anderson
[1] P. Harrison,et al. Topical microbicides for disease prevention: status and challenges. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] R. Puri,et al. Human Cytokines: Their Role in Disease and Therapy , 1995 .
[3] B. Herold,et al. Development of Topical Microbicides for Prevention of Human Immunodeficiency Virus and Herpes Simplex Virus , 2003, American journal of reproductive immunology.
[4] John D Lambris,et al. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b. , 2002, Virology.
[5] R. Hayes,et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. , 2000, The Journal of infectious diseases.
[6] L. Zaneveld,et al. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. , 1999, Contraception.
[7] H. Rees,et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women , 2003, AIDS.
[8] Myron S. Cohen,et al. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis , 1998, The Lancet.
[9] R. Lehrer,et al. NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. , 2003, Antimicrobial agents and chemotherapy.
[10] A. Wald,et al. Herpes simplex virus: the importance of asymptomatic shedding. , 2000, The Journal of antimicrobial chemotherapy.
[11] D. Marcellino,et al. Poly(sodium 4-styrene sulfonate): an effective candidate topical antimicrobial for the prevention of sexually transmitted diseases. , 2000, The Journal of infectious diseases.
[12] H. Rees,et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial , 2002, The Lancet.
[13] C. Crumpacker,et al. Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. , 2000, The Journal of infectious diseases.
[14] S. S. Olmsted,et al. Tests of BufferGel for Contraception and Prevention of Sexually Transmitted Diseases in Animal Models , 2001, Sexually transmitted diseases.
[15] Robert A. Anderson,et al. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). , 2001, Contraception.
[16] J. H. van de Wijgert,et al. Phase 1 Trial of the Topical Microbicide BufferGel: Safety Results From Four International Sites , 2001, Journal of acquired immune deficiency syndromes.
[17] D. Marcellino,et al. Mandelic Acid Condensation Polymer: Novel Candidate Microbicide for Prevention of Human Immunodeficiency Virus and Herpes Simplex Virus Entry , 2002, Journal of Virology.
[18] S. Wahl,et al. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. , 1997, Blood.
[19] R. Longnecker,et al. Herpesvirus Entry: an Update , 2003, Journal of Virology.
[20] S. Straus,et al. Specificity and affinity of binding of herpes simplex virus type 2 glycoprotein B to glycosaminoglycans , 1997, Journal of virology.
[21] R. Roller,et al. Characterization of a BHK(TK-) cell clone resistant to postattachment entry by herpes simplex virus types 1 and 2 , 1997, Journal of virology.
[22] D. Anderson,et al. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. , 2001, The Journal of infectious diseases.
[23] D. Marcellino,et al. Bile Salts: Natural Detergents for the Prevention of Sexually Transmitted Diseases , 1999, Antimicrobial Agents and Chemotherapy.
[24] L. van Damme,et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers , 2000, AIDS.
[25] J. Turpin. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV , 2002, Expert opinion on investigational drugs.
[26] B. Herold,et al. Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity , 1991, Journal of virology.
[27] R. Eisenberg,et al. Examination of the Kinetics of Herpes Simplex Virus Glycoprotein D Binding to the Herpesvirus Entry Mediator, Using Surface Plasmon Resonance , 1998, Journal of Virology.
[28] D. Anderson,et al. Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. , 1999, Biology of reproduction.
[29] L. van Damme,et al. Safety and Acceptability of Penile Application of 2 Candidate Topical Microbicides: BufferGel and PRO 2000 Gel: 3 Randomized Trials in Healthy Low‐Risk Men and HIV‐Positive Men , 2003, Journal of acquired immune deficiency syndromes.
[30] M. Hirsch,et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities , 1996, Antimicrobial agents and chemotherapy.
[31] R. Sekulovich,et al. Limited variability of glycoprotein gene sequences and neutralizing targets in herpes simplex virus type 2 isolates and stability on passage in cell culture. , 1998, The Journal of infectious diseases.
[32] D. Bernstein,et al. The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. , 1999, The Journal of infectious diseases.
[33] F. Krebs,et al. A Broad-Spectrum Microbicide with Virucidal Activity against Sexually Transmitted Viruses , 1999, Antimicrobial Agents and Chemotherapy.
[34] B. Cullen,et al. Molecular basis of latency in pathogenic human viruses. , 1991, Science.
[35] Robert A. Anderson,et al. Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. , 2002, Journal of andrology.
[36] G. Doncel,et al. Evaluation of poly(styrene-4-sulfonate) as a preventive agent for conception and sexually transmitted diseases. , 2000, Journal of andrology.
[37] P. Spear,et al. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate , 1989, Journal of virology.
[38] D. Malamud,et al. Sodium Dodecyl Sulfate and C31G as Microbicidal Alternatives to Nonoxynol 9: Comparative Sensitivity of Primary Human Vaginal Keratinocytes , 2000, Antimicrobial Agents and Chemotherapy.
[39] G. Wilbanks,et al. Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens , 1997, Antimicrobial agents and chemotherapy.
[40] D. Phillips,et al. Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. , 1996, Biology of reproduction.
[41] N. Cheshenko,et al. Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. , 2002, The Journal of general virology.